CABA-201, an experimental cell therapy for lupus and other autoimmune disorders, has been granted fast track status by the U.S. Food and Drug Administration (FDA). The FDA awards this designation to therapies with the potential to address unmet medical needs in the treatment of serious conditions. Fast track status…
Lupkynis (voclosporin) is now approved in Switzerland to treat adults with active lupus nephritis, a complication of lupus characterized by kidney damage and inflammation. The approval specifically covers the treatment, given along immunosuppressants, for adults with active class 3, 4, and 5 lupus nephritis — three subtypes of the…
The Lupus Foundation of America (LFA) is calling on the community to help increase visibility and promote education about the autoimmune disease throughout the month of May — thereby marking Lupus Awareness Month. “All too often people with lupus hear that they don’t ‘look’ sick. This is why…
Severe flare-ups of systemic lupus erythematosus (SLE) among patients were associated with a markedly higher risk of stroke, according to the results of a population-based study in Taiwan that analyzed data spanning 16 years. Importantly, an overall elevated stroke risk was seen for younger adults with SLE who had…
Toni Braxton is hoping to strike a chord with people with lupus via Aurinia Pharmaceuticals‘ “Get Uncomfortable” campaign: the singer-songwriter wants to empower fellow patients to prioritize kidney health as a key part of their care. Braxton, a Grammy Award-winning singer, and an actress, producer, and entrepreneur, was…
The Lupus Research Alliance (LRA) is funding four research projects aiming to explore molecular targets that could lead new ways of treating lupus. The grants were given as part of the LRA’s Lupus Mechanisms and Targets Award (LMTA) program, which offers up to $600,000 over three years…
Seven projects led by research teams from the U.S. and Europe have been announced as the recipients of the latest round of Lupus Research Alliance (LRA) Lupus Innovation Award (LIA) grants, which can total up to $300,000. The awards provide support — up to $150,000 annually for two…
JW Therapeutics has received approval from Chinese authorities to open a clinical trial of its CAR T-cell therapy, relmacabtagene autoleucel (relma-cel), in systemic lupus erythematosus (SLE) patients with moderate-to-severe and treatment-resistant active disease. Although not approved for SLE or other autoimmune disorders, relma-cel is available under the…
Viral infections with cytomegalovirus, known as CMV, are highly prevalent in children with systemic lupus erythematosus (SLE), and are linked to high disease activity and poor outcomes, a study in China reports. Given that anti-CMV treatment can reduce disease activity and flares, the virus’ early identification and treatment…
Over 18 months, the approved therapy Lupkynis (voclosporin) lessened inflammation and prevented further kidney damage in systemic lupus erythematosus (SLE) patients with active lupus nephritis, without any signs of kidney-related toxicity seen with similar treatments. New top-line data show participants in the Lupkynis treatment arm of the now…